Author

S. Modi

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer

Abstract Wide variation in outcomes is observed for patients with hormone-receptor-positive metastatic breast cancer (MBC) receiving first-line CDK4/6 inhibitors plus endocrine therapy (CDK4/6i+ET). Although front-line escalation strategies are beginning to enter clinical practice, assigning patients to intensified or...

Luca Boscolo Bielo, F. Sánchez-Vega, Subhiksha Nandakumar et al. · Research Square · 0 citations

Aug 2026

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

PURPOSE EA1181 (ClinicalTrials.gov identifier: NCT04266249) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This report focuses on the secondary end points of pathologic...

N. Tung, Feng-Min Zhao, A. DeMichele et al. · Journal of Clinical Oncology · 1 citation